# Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

> **NCT00446225** · PHASE3 · COMPLETED · sponsor: **Spanish Lung Cancer Group** · enrollment: 174 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabin
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00446225
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-15
- **Primary completion:** 2012-04-11
- **Final completion:** 2012-12
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446225, "Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00446225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*